…And all through the town not a creature was stirring except for some struggling to stay awake throughout the night shift….
So reads a newspaper ad for a federally-controlled substance in prescription drug form that is marketed for ES caused by SWD or OSA.
Don’t know what that means?
Come on. Where have you been?
Like ED for erectile dysfunction, PE for premature ejaculation, and GERD for gastrointestinal reflux disorder, these are the new marketing names for conditions that drug companies want to sell you drugs for.
ES = excessive sleepiness
SWD = shift work disorder
OSA = obstructive sleep apnea
The drug company’s online ads feature a fireman, a police officer, a construction worker. I am very sensitive to Read more »
*This blog post was originally published at Health News Review*
Give me your medication list and I’ll tell you your health problems. It happens every day in emergency rooms across the country as confused elderly patients present for an acute problem unable to describe their past medical history, but equipped with a list of medications in their wallet:
Metformin = Type-2 diabetes
Synthroid = Hypothyroidism
Lipitor + Altace + Lasix + Slo-K = Ischemic cardiomyopathy
Lexapro = A little anxious or depressed
Viagra = Well, you know…
I bet I’d be right better than 90 percent of the time. Now, imagine you’re a pharmaceutical company wanting to target people with those chronic diseases. Where might you find them?
No problem. Just pay the insurers to provide you patients’ drug lists. No names need be exchanged in keeping with HIPAA requirements. But the drugs list attached to folks’ cable TV box? Perfect. You’re in — with no legal strings attached. Then, according to the Wall Street Journal, just fire away with that targeted direct-to-consumer advertising on TV, courtesy of your local healthcare insurance provider.
No wonder our healthcare industry movers and shakers love the electronic medical record. Healthcare privacy? What healthcare privacy?
-WesMusings of a cardiologist and cardiac electrophysiologist.
*This blog post was originally published at Dr. Wes*
Just five days ago we wrote about an American journalist’s observations of medicalization of one problem sometimes observed after menopause: Vaginal atrophy.
Today we see that this disease-mongering trend has popped up in Australia as well. This should be no surprise. Such campaigns are usually led by multinational pharmaceutical companies and their advertising and public relations agencies.
What caught our eye was an article on a women’s health foundation website — a foundation that posts a pretty thin excuse for why it won’t tell you its source of funding. Its article on vaginal atrophy uses classic disease-mongering language:
“Ask a woman over the age of 50 about the ‘signs of ag[e]ing’ and she’ll most likely lament about grey hairs, wrinkles and certain body parts having lost their youthful perkiness. What she probably won’t mention is that is that things are ageing “downstairs” too; up to 40% of postmenopausal women show signs of vaginal atrophy.”
The silent epidemic that no one talks about. The huge prevalence estimate — where does that 40 percent figure come from? Read more »
*This blog post was originally published at Gary Schwitzer's HealthNewsReview Blog*
If you google “low testosterone” you’ll see lots of ads for testosterone replacement. Some are from pharmaceutical companies that sell testosterone, others from obvious snake-oil salesmen.
Both types of ads list vague sets of symptoms, encourage you to believe that they are pathologic, and want to sell you something to make you better. For example, the pharmaceutical company Solvay gives you a handy guide for speaking to your doctor, and a quiz to see if you have “low T.” The quiz asks some questions that may be useful, but also asks very general questions about your sense of well being. Read more »
*This blog post was originally published at Science-Based Medicine*
How effective is direct-to-consumer drug advertising? Some think that drug ads should be banned altogether, saying that it encourages patients to ask their doctors for expensive, brand name prescription drugs. It turns out their fears may be overblown.
NPR’s Shots blogs about a recent study looking at the effectiveness of these ads. The numbers, for the pharmaceutical companies anyways, are not encouraging. Read more »
*This blog post was originally published at KevinMD.com*